Castle Biosciences’ 2026 Q2 results continue to reflect growth in core products like DecisionDx-Melanoma and TissueCypher, offset by revenue pressure from the loss of Medicare reimbursement on DecisionDx-SCC. The company’s business model relies heavily on multi-analyte assays and algorithmic analysis to deliver personalized clinical insights, underscored by CLIA certification and broad third-party payor reimbursements. Growth initiatives hinge on expanding test indications, clinical validation, and strategic investments in pipeline assets such as AdvanceAD-Tx. However, sustained net losses and reimbursement risk weigh on financial stability, with the firm maintaining a strong liquidity position as it invests in commercialization and R&D.